Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05577741
Other study ID # 2022-A01156-37
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 29, 2022
Est. completion date February 2025

Study information

Verified date March 2023
Source Centre Hospitalier Henri Laborit
Contact Nematollah JAAFARI, Professor
Phone 0033(0)5 16 52 61 18
Email nemat.jaafari@ch-poitiers.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical study investigates the effects of enriched environment on the risk of relapse in alcoholic patients. 135 patients hospitalized for an alcoholic addiction will be recruited and randomized in two groups: one group will receive standard of care, the other group will receive a treatment with enriched environment. The enriched environment consists of six sessions of virtual reality (20 minutes) in a multi-sensory pod and six sessions (20 minutes) of bike activity with cognitive tasks while pedalling. The multi-sensory virtual reality pod allows mindfulness practice and allows patients to be in immersive situations that may trigger cues in order to help them in craving management. The bike consists in the combination of a pedal set and a touch pad on which cognitive training games are offered. This tool thus makes it possible to simultaneously stimulate motor skills and cognition by means of bicycle-game coupling. Patients are then followed during 3 months and a half.


Recruitment information / eligibility

Status Recruiting
Enrollment 135
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Any patient hospitalized at the Henri Laborit Hospital for alcohol addiction, on an opened unit for at least 48 hours; - Woman or man aged between 18 and 65 inclusive - Severe alcohol use disorder according to the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders - Benefit from social security or benefit from it through a third party in accordance with French law on research involving the human person - Have signed the informed consent form after receiving written information. Exclusion Criteria: - Disabling cognitive disorders - Cardiological pathologies that could compromise the participation of patients, detected by an ECG. - Advanced pulmonary, renal, and hepatic diseases, or any unstable and serious medical conditions that could compromise the patient's participation in the study, subject to the judgment of the doctor - Hypertension - Ataxia - Uncompensated and unstable psychiatric pathology - Susceptibility to cybersickness - Pregnant or breastfeeding woman - Simultaneous participation in another trial - Any other current addiction, except addiction to tobacco and benzodiazepines - Employee of the investigator or of the clinical study site - Patients protected by law - People not covered by state health insurance - Patients who in the opinion of the investigator are unable to complete the questionnaires

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Multisensory virtual reality pod (SENSIKS©)
Six sessions of 20 minutes of mindfulness.
Cognitive bike (Vélo-cognitif®)
Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
Other:
Standard treatment
Standard of care treatment

Locations

Country Name City State
France Centre Hospitalier Henri Laborit Poitiers

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Henri Laborit

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Alcoholic relapse Relapse at 2 weeks (after Day 10), defined by the consumption of at least 5 glasses per occasion, or by consumption at least 5 times a week, assessed by the Time Line Follow Back, a beathalyser or a significant increase in Carbohydrate Deficient Transferrin and Gamma-GT.
We will consider a relapse to have occurred if at least one of the three indicators points to a relapse: 1) if in the TLFB the patient indicates consumption of at least 5 times per week or at least 5 drinks per occasion; 2) if there is a significant increase in CDT and GGT since the D10 blood test, and 3) If the breathalyser is positive. We will consider patients as non-relapsers if none of these indicators (TLFB, CDT and GGT, breathalyzer) is positive.
2 weeks
Secondary Alcoholic relapse Relapse at 1 month (after Day 10), defined by the consumption of at least 5 glasses per occasion, or by consumption at least 5 times a week 1 month
Secondary Alcoholic relapse Relapse at 3 months (after Day 10), defined by the consumption of at least 5 glasses per occasion, or by consumption at least 5 times a week 3 months
Secondary Explicit craving The effect of intervention on explicit craving, assessed by the Obsessive Compulsive Drinking Scale and the cue craving induction protocol. Day 10
Secondary Implicit craving The effect of intervention on implicit craving, assessed by an Implicit Association Test, a test of the seeking for alcohol-related stimuli, and a visual research test for alcohol-related stimuli (eye-tracking) Day 10
Secondary Mindfulness skills The effect of intervention on mindfulness skills, assessed by a questionnaire (Five Facets Mindfulness Questionnaire -15) Day 10
Secondary Perception of the richness of the daily environment The effect of the intervention on the perceived richness of the daily environment, assessed by a questionnaire. Day 10
See also
  Status Clinical Trial Phase
Completed NCT00758277 - Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients Phase 3